ALVO Key Statistics, Chart & Performance
The current stock price of ALVO is 4.64 USD. In the past month the price decreased by -8.55%. In the past year, price decreased by -59.68%.
ALVO Latest News, Press Relases and Analysis
ALVO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.36 | 406.92B | ||
| AMGN | AMGEN INC | 15.79 | 186.00B | ||
| GILD | GILEAD SCIENCES INC | 15.26 | 155.09B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.68 | 117.51B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.08 | 76.06B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 928.02 | 62.53B | ||
| INSM | INSMED INC | N/A | 44.10B | ||
| NTRA | NATERA INC | N/A | 32.88B | ||
| BIIB | BIOGEN INC | 10.8 | 26.52B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.23 | 20.71B | ||
| INCY | INCYTE CORP | 15.81 | 19.93B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.21B |
Related stock screener links
About ALVO
Company Profile
Alvotech is a biotechnology company, which engages in the development and manufacture of biosimilar medicines. The firm is focused on the development and manufacture of biosimilar medicines for patients globally. The company is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). The company has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
Company Info
ALVOTECH SA
9, Rue De Bitbourg
Luxembourg LU
Employees: 1011
Phone: 35244224500
ALVOTECH SA / ALVO FAQ
What does ALVOTECH SA do?
Alvotech is a biotechnology company, which engages in the development and manufacture of biosimilar medicines. The firm is focused on the development and manufacture of biosimilar medicines for patients globally. The company is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). The company has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
Can you provide the latest stock price for ALVOTECH SA?
The current stock price of ALVO is 4.64 USD. The price increased by 0.87% in the last trading session.
What is the dividend status of ALVOTECH SA?
ALVO does not pay a dividend.
How is the ChartMill rating for ALVOTECH SA?
ALVO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
How is the market expecting ALVO stock to perform?
10 analysts have analysed ALVO and the average price target is 11.12 USD. This implies a price increase of 139.61% is expected in the next year compared to the current price of 4.64.
Is ALVOTECH SA (ALVO) expected to grow?
The Revenue of ALVOTECH SA (ALVO) is expected to grow by 43.22% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the market capitalization of ALVO stock?
ALVOTECH SA (ALVO) has a market capitalization of 1.45B USD. This makes ALVO a Small Cap stock.
ALVO Technical Analysis
ALVO Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to ALVO. ALVO has a medium profitability rating, but doesn't score so well on its financial health evaluation.
ALVO Financial Highlights
Over the last trailing twelve months ALVO reported a non-GAAP Earnings per Share(EPS) of 0.2. The EPS increased by 122.99% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 11.26% | ||
| ROA | 4.55% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ALVO Forecast & Estimates
10 analysts have analysed ALVO and the average price target is 11.12 USD. This implies a price increase of 139.61% is expected in the next year compared to the current price of 4.64.
For the next year, analysts expect an EPS growth of 135.17% and a revenue growth 43.22% for ALVO